Showing results (1-10 of 40) with videos related to
Sort By:
Pageof 4
Australian Prescriber|April 23, 2026
Vitamin B12 deficiency: testing and treatmentDarya Bedz, Cecily ForsythJournal of Clinical Medicine|November 14, 2023
T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma-An UpdateShalini Balendran, Constantine Tam, Matthew KuBlood|January 14, 2025
Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitorsConstantine S Tam, Shalini Balendran, Piers BlomberyLeukemia & Lymphoma|July 25, 2013
Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyureaEmma Verner, Cecily Forsyth, Andrew GriggLeukemia & Lymphoma|August 14, 2023
Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national surveyAlexandra Murton, Cecily Forsyth, David M Ross, et al.European Heart Journal. Case Reports|August 4, 2021
Proteasome inhibitor-induced coronary vasospasm in multiple myeloma: a case reportPhilopatir Mikhail, James Rogers, Cecily Forsyth, et al.British Journal of Haematology|August 27, 2010
The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathwayO Giles Best, Nisha Singh, Cecily Forsyth, et al.Ejhaem|March 24, 2025
Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With RuxolitinibLiesl A Butler, Cecily Forsyth, Claire Harrison, et al.Leukemia & Lymphoma|December 14, 2011
The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory diseaseO Giles Best, Yiping Che, Nisha Singh, et al.Pageof 4